Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Launched by UNIVERSITY HOSPITAL, ANTWERP · Aug 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for adults with acute myeloid leukemia (AML) who have not responded to previous therapies or whose cancer has returned after treatment. The researchers are looking at the combination of two medications: ABT-199, also known as venetoclax, and 6-mercaptopurine. The aim is to see how effective this combination is in helping patients with relapsed or refractory AML. The trial is currently recruiting participants aged 18 and older who meet specific criteria, including having experienced relapses after intense chemotherapy or other treatments.

If you decide to participate, you will receive the study medications and be closely monitored by the medical team throughout the trial. It’s important to note that you cannot be part of this study if you have certain health conditions, are currently pregnant or breastfeeding, or are involved in another clinical trial. Overall, this trial offers a potential new option for patients with difficult-to-treat AML, and the findings could help improve treatment for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Relapsed or refractory AML
• • Relapsed after or refractory to at least one cycle of intensive chemotherapy (combination of ara-c/anthracyclin) or four cycles of HMA (hypomethylating agents)
• • Adult AML aged \>/= 18 years
• • WHO performance status: grade 0-2 at the time of enrollment
• • ABT-199 (venetoclax) and PA-naïve. Patient may be prior exposed but not refractory to venetoclax. In case of previous therapy with venetoclax inclusion is only possible after discussion with the PI.
• Exclusion Criteria:
• • Participation in any other interventional clinical trial during the study period
• • Active presence (or known history of) central nervous system disease
• • History or concomitant presence of any other malignancy, except for non-melanoma skin cancer, carcinoma in situ of the cervix, any other effectively treated malignancy that has been in remission for \>5 years or that is highly likely to be cured at the time of enrollment.
• • Active HIV, hepatitis B or hepatitis C infection
• • Use of any antitumoral agent within less than 5 times the half-life of the agent prior to the screening bone marrow examination. After the screening bone marrow examination, the use of cytoreductive treatment prior to the initiation of venetoclax is permitted in order to lower the WBC-count to \<25 000/µl (e.g. hydroxyurea).
• • Medical conditions requiring chronic therapy of moderate or strong CYP3A4 inducers without alternative
• • Patients with known hypersensitivity to the active substance or to any of the excipients
• • Pregnant or breastfeeding woman
• • Active uncontrolled systemic infection